Research and Markets: Examine Financial Performance of Merck & Co Pharmaceutical Company with This Report.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c43328) has announced the addition of the latest report from Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. "Merck & Co Pharmaceutical Company Intelligence Report" to their offering. Established in 1891, Merck & Co discovers, develops, manufactures and markets vaccines and pharmaceutical medicines to address unmet medical needs. The company operates on a global basis and is represented in more than 200 countries. Merck's headquarters are based in Whitehouse Station, NJ. Current Growth Drivers Merck currently markets six blockbuster products with sales in excess of US$1 billion, however, due to patent expiries and increasing competition in certain markets, only four of these will form the basis of future sales growth: Cozaar (losartan potassium) was the first angiotensin-II receptor antagonist selective for AT1 receptors to be developed for the treatment of hypertension. It was jointly developed with DuPont Merck (now Bristol-Myers Squibb), as was Hyzaar, a combination of Cozaar and hydrochlorothiazide hydrochlorothiazide /hy·dro·chlo·ro·thi·a·zide/ (-klor?o-thi´ah-zid) a thiazide diuretic, used for treatment of hypertension and edema. hy·dro·chlo·ro·thi·a·zide n. Abbr. . Zetia/Ezetrol (ezetimibe), a cholesterol absorption inhibitor Cholesterol absorption inhibitors are a class of compounds that prevents the uptake of cholesterol from the small intestine into the circulatory system. How They Work There are two sources of cholesterol in the upper intestine: dietary (from food) and biliary (from bile). , was developed by the Merck/Schering-Plough joint venture and is indicated for the treatment of hypercholesterolaemia. Vytorin/Inegy (ezetimibe+simvastatin simvastatin /sim·va·stat·in/ (sim´vah-stat?in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the risks associated ) is a fixed-combination tablet that offers a novel approach to cholesterol management. It was jointly developed and launched by the Merck/Schering-Plough joint venture. Singulair (montelukast montelukast /mon·te·lu·kast/ (mon?te-loo´kast) a leukotriene antagonist used as the sodium salt in prophylaxis and chronic treatment of asthma. mon·te·lu·kast n. ) is a once-daily, long-acting oral leukotriene leukotriene /leu·ko·tri·ene/ (-tri´en) any of a group of biologically active compounds derived from arachidonic acid that function as regulators of allergic and inflammatory reactions. D4-receptor antagonist indicated for the treatment of asthma. Cancidas (caspofungin acetate) is a water-soluble semi-synthetic agent derived from a fermentation product discovered at Merck's laboratories in Madrid. It acts by inhibiting glucan glucan /glu·can/ (gloo´kan) any polysaccharide composed only of recurring units of glucose; a homopolymer of glucose. glu·can n. A polysaccharide, such as cellulose, that is a polymer of glucose. synthase synthase /syn·thase/ (-thas) a term used in the names of some enzymes, particularly lyases, when the synthetic aspect of the reaction is dominant or emphasized. syn·thase n. , the enzyme responsible for maintaining the fungal cell wall and is thus fungicidal against a broad range of pathogens including those that have become resistant to currently-used antifungal drugs. Key Topics Covered Include: - Principal Operating Results - Latest Results - Current Growth Drivers - Key Late-Phase Products Reaching the Market Place - Key Late-Stage Products - Key Early-Stage Products - Financial Performance 2005 - Sales and Market Position - Capital Expenditure - Capital Expenditure By Function - R&D Expenditure - Divisional Performance - Vioxx/Ceoxx - R&D Strategy - Key R&D Projects - R&D Pipeline Overview - Discontinued R&D projects For more information visit http://www.researchandmarkets.com/reports/c43328 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion